CEO of Pfizer Creates New Treatment Pill Projected to be Available by the End of 2021

CEO of Pfizer Creates New Treatment Pill Projected to be Available by the End of 2021

The Pfizer pill is described as a “game-changer.”

An oral pill is expected to treat variants of COVID-19. The CEO of Pfizer announced that an antiviral treatment for the disease could be available to the public by the end of 2021.

A news article in the UK says Pfizer is currently conducting trials in the U.S. and Belgium, where adult volunteers are taking pills to help find a “cure” for COVID-19. Pfizer CEO Albert Bourla said “it is accurate” to say the company is “working on” such therapies. The company is actually testing two antivirals, one that is injected and one that is taken orally.

Bourla explained Pfizer is focusing on the oral option because it provides multiple advantages, including people not coming to the hospital. He described the oral antiviral pill as a “game changer.” He says the end of the year is a reasonable time frame for availability to the public, all depending on the success of the trials and FDA approval.

Although it’s still new, Pfizer announced the beginning of Phase 1 clinical trials of the drug - PF-07321332 - in late March. An article says it’s designed to work by stopping SARS-CoV-2 from replicating in the cell.

"Tackling the Covid-19 pandemic requires both prevention via vaccine and targeted treatment for those who contract the virus," said Mikael Dolsten, Pfizer's chief scientific officer, "Given the way that SARS-CoV-2 is mutating and the continued global impact of COVID-19, it appears likely that it will be critical to have access to therapeutic options both now and beyond the pandemic."

More than 296 million* COVID-19 vaccines have been administered in the U.S. so far.

About the Author

Shereen Hashem is the Associate Content Editor for Occupational Health & Safety magazine.

Product Showcase

  • The MGC Simple Plus

    The MGC Simple Plus

    The MGC Simple Plus is a simple-to-use, portable multi-gas detector that runs continuously for three years without needing to be recharged or routinely calibrated after its initial charge and calibration during manufacturing. The detector reliably tests a worksite’s atmosphere for hydrogen sulfide, carbon monoxide, oxygen and combustible gases (LEL). Additionally, it is durable enough to withstand the harshest treatment and environments, which is why it has an IP 68 rating. The MGC Simple Plus is also compatible with a variety of accessories, such as Gas Clip Technologies’ new GCT External Pump. Visit gascliptech.com for more information. 3

  • Magellan X Pte Ltd

    Hesitate No More with SOL-X Connected Worker Health & Safety Solution

    According to the National Safety Council, work-related medically consulted injuries total 4.26 million in 2021 in USA alone. SOL-X solution prevents “human factors” safety issues by anticipating incidents and improving compliance workflows. Leverages digital technologies (IIoT, AI and analytics) to predict patterns from occurring and make informed decisions. Control Of Work - gets rid of tedious paperwork and experience digital workflows. Crew Protect - maximises safety and situational awareness with health trackers and situational indicators. Award-winning Intrinsically Safe SmartWatch – innovative features that enable near real-time visibility and connected well-being. Works well with major connectivity protocols like Wi-Fi, Bluetooth, and Long-Range Bluetooth! 3

Featured